Stockreport

The Biotech Stock That's Too Risky for Most Investors [Yahoo! Finance]

Recursion Pharmaceuticals, Inc. - Class A  (RXRX) 
PDF Recursion has several cancer therapy candidates in early-stage clinical trials. Drug trials often fail. 10 stocks we like better than Recursion Pharmaceuticals › [Read more]